Dr. Edmund Capparelli Honored with Award from ACCP

The IMPAACT Network congratulates Dr. Edmund Capparelli as the 2026 Roger Jelliffe Individualized Therapy Award recipient! This award is given annually by the American College of Clinical Pharmacology (ACCP) to recognize an individual who significantly advances the field of personalized medicine by improving the use of drugs or biologics in patients. 

Dr. Capparelli is a professor of Clinical Pharmacology at the Skaggs School of Pharmacy & Pharmaceutical Sciences at the University of California, San Diego. He has worked with IMPAACT for over two decades, serving as protocol pharmacologist on over 25 studies. He is currently serving as a member of the IMPAACT Pharmacometric Service Core and as an emeritus to the IMPAACT Therapeutics Scientific Committee.  

“Edmund’s work has been critical not only to our Network but has helped develop the foundation for assessing the pharmacokinetics and pharmacodynamics of novel therapeutics for women and children worldwide,” said Sharon Nachman, IMPAACT Network Chair. 

Dr. Capparelli’s work spans across key Network research priorities, supporting PK research in pregnancy and postpartum (P1026s and IMPAACT 2026), long-acting injectable ARVs for children (IMPAACT 2017/MOCHA and IMPAACT 2036/CRAYON), and broadly neutralizing antibodies or bNAbs (IMPAACT 2042/Tatelo Plus, IMPAACT 2037, and P1115).   

Dr. Capparelli will be honored for his achievements during the 2026 ACCP Annual Meeting.